title: Detection of Epstein-Barr virus in invasive breast cancers.
abstract: BACKGROUND
  Epstein-Barr virus (EBV) may be a cofactor in the development of different malignancies, including several types of carcinomas. In this study, we investigated the presence of EBV in human breast cancers.
  
  
  METHODS
  We used tissues from 100 consecutive primary invasive breast carcinomas, as well as 30 healthy tissues adjacent to a subset of the tumors. DNA was amplified by use of the polymerase chain reaction (PCR), with the primers covering three different regions of the EBV genome. Southern blot analysis was performed by use of a labeled EBV BamHI W restriction fragment as the probe. Infected cells were identified by means of immunohistochemical staining, using monoclonal antibodies directed against the EBV nuclear protein EBNA-1.
  
  
  RESULTS
  We were able to detect the EBV genome by PCR in 51% of the tumors, whereas, in 90% of the cases studied, the virus was not detected in healthy tissue adjacent to the tumor (P<.001). The presence of the EBV genome in breast tumors was confirmed by Southern blot analysis. The observed EBNA-1 expression was restricted to a fraction (5%-30%) of tumor epithelial cells. Moreover, no immunohistochemical staining was observed in tumors that were negative for EBV by PCR. EBV was detected more frequently in breast tumors that were hormone-receptor negative (P =.01) and those of high histologic grade (P =.03). EBV detection in primary tumors varied by nodal status (P =.01), largely because of the difference between subjects with more than three lymph nodes versus less than or equal to three lymph nodes involved (72% versus 44%).
  
  
  CONCLUSIONS
  Our results demonstrated the presence of the EBV genome in a large subset of breast cancers. The virus was restricted to tumor cells and was more frequently associated with the most aggressive tumors. EBV may be a cofactor in the development of some breast cancers.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, EPI 99-32, Pharmacologie Expérimentale et Clinique, Hôpital Saint Louis, Institut de Génétique Moléculaire, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Bonnet
authors.forename: J M
authors.initials: JM
authors.lastname: Guinebretiere
authors.forename: E
authors.initials: E
authors.lastname: Kremmer
authors.forename: V
authors.initials: V
authors.lastname: Grunewald
authors.forename: E
authors.initials: E
authors.lastname: Benhamou
authors.forename: G
authors.initials: G
authors.lastname: Contesso
authors.forename: I
authors.initials: I
authors.lastname: Joab
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015139:Blotting, Southern; D001943:Breast Neoplasms / Q000473:pathology* / Q000821:virology*; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length
chemical_list: D004279:DNA, Viral